|
CSHL licenses technologies developed by its scientists to the biotechnology and pharmaceutical market for purposes of drug discovery, target validation, and/or therapeutic development. CSHL scientists work on a wide range of disease related topics and are on the cutting edge of drug discovery research in areas of oncology, neurobiology, and development.
CSHL also has played a seminal role in discovering and developing new applications the new field of RNA Interference (RNAi) and has made these technologies widely available to the scientific community.
Click here for more details on Dr. Greg Hannon’s research on RNAi.
|
